GGTI-2166
GGTI-2166 is a geranylgeranyltransferase I (GGTase I) inhibitor. GGTI-2166 blocks geranylgeranylation modification of target proteins. GGTI-2166 inhibits RANKL- or TNF-α-induced pre-osteoclast formation and TRAP activity. GGTI-2166 is applicable to research on osteoclast differentiation.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 478908-51-9
- Formule: C25H30N4O3
- Masse moléculaire:434.54
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
In Vitro
GGTI-2166 (0.3-3 μM; 2 days) dose-dependently inhibits RANKL-induced osteoclast precursor formation in mouse bone marrow-derived M-CSF-dependent monocytes (MD cells)[1].
GGTI-2166 (1.25-10 μM; 3 days) inhibits RANKL-induced osteoclast precursor formation in RAW 264.7 mouse monocytes in a dose-dependent manner[1].
GGTI-2166 (1-3 μM; 40 h) inhibits the geranylgeranylation of 21-26 kDa small G proteins in RAW 264.7 mouse monocytes[1].
GGTI-2166 (1 μM; 2 days) inhibits the formation of osteoclast precursors in TNF-α-induced mouse bone marrow-derived M-CSF-dependent monocytes (MD cells)[1].
GGTI-2166 (1 μM; 3 days) inhibits TNF-α-induced differentiation of RAW 264.7 mouse monocytes into osteoclast precursors[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 478908-51-9
-
Masse moléculaire 434.54
-
Formule C25H30N4O3
-
SMILES
C(N[C@H](C(OC)=O)CC(C)C)(=O)C1=C(C=C(NCC2=CN=CN2)C=C1)C3=C(C)C=CC=C3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Woo JT, et al. Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha). Biochem Pharmacol. 2005;69(1):87-95. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GGTI-2166 Related Classifications
HY-114159 Related Classifications
Powered by Bioz